Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
National Institutes of Health · Department of Health and Human Services
At a glance
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) is an open federal grant opportunity from the National Institutes of Health (Department of Health and Human Services). Applications are due November 10, 2026. Individual awards are listed as up to $150K, with about 20 awards expected and $5.1M in total estimated funding. Applicant types listed as eligible include state governments, county governments, city or township governments, special district governments, independent school districts and 10 more. Cost sharing is not required. It is funded under Assistance Listing 93.394 (Cancer Detection and Diagnosis Research).
Summary assembled from the official notice's fields. The official notice governs.
Key facts
- Posted
- Jun 3, 2026
- Close date
- Nov 10, 2026
- Archive date
- Jan 9, 2027
- Est. award date
- Dec 1, 2026
- Award floor
- Not specified
- Award ceiling
- $150,000
- Est. total funding
- $5,100,000
- Expected awards
- 20
- Cost sharing
- Not required
- Funding instrument
- Grant
- Opportunity category
- Discretionary
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public colleges & universities
- Federally recognized tribal governments
- Public & Indian housing authorities
- Native American tribal organizations
- 501(c)(3) nonprofits
- Nonprofits without 501(c)(3) status
- Private colleges & universities
- For-profit organizations (not small businesses)
- Small businesses
- Others (see notice)
Additional information on eligibility (from the notice)
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Based on the published notice. Review the official notice for complete eligibility requirements.
What it funds
Official synopsis as published by the agency, formatted for readability.
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Assistance Listing
What is an ALN?Reported obligations under ALN 93.394
Historical data · not a predictionAgency contact (as published)
National Institutes of Health
Kelly.crotty@nih.gov
301-402-2541
Quick answers
When is the deadline for this opportunity?
According to the official notice, applications are due November 10, 2026. Confirm the deadline and submission time on Grants.gov before applying.
Who is eligible to apply for this opportunity?
The official notice lists these applicant types as eligible: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public colleges & universities, Federally recognized tribal governments, Public & Indian housing authorities, Native American tribal organizations, 501(c)(3) nonprofits, Nonprofits without 501(c)(3) status, Private colleges & universities and 3 more. Additional restrictions may apply; review the full notice.
How much funding is available through this opportunity?
Per the notice, individual awards are listed as up to $150k, total estimated program funding is $5,100,000 and the agency expects to make about 20 awards.
How do I apply for this opportunity?
Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity RFA-CA-27-001), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.
Related open opportunities
Matched on shared Assistance Listings, agency, categories and eligible applicant types.
Forecast to Publish a Notice of Funding Opportunity for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
National Institutes of Health- Award range
- Amount not specified
- Est. close
- Oct 30, 2025 (est.)
- Who can apply
- State governments, County governments, Independent school districts and 8 more
Forecast to Publish a Notice of Funding Opportunity for Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Allowed)
National Institutes of Health- Award range
- Amount not specified
- Est. close
- Oct 30, 2025 (est.)
- Who can apply
- State governments, County governments, Independent school districts and 8 more
NIH Research Program Projects (Parent P01 Clinical Trial Optional)
National Institutes of Health- Award range
- Amount not specified
- Est. close
- Sep 25, 2026 (est.)
- Who can apply
- State governments, County governments, City or township governments and 12 more
Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
National Institutes of Health- Award range
- Amount not specified
- Est. close
- Oct 5, 2026 (est.)
- Who can apply
- State governments, County governments, City or township governments and 12 more
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
National Institutes of Health- Award range
- Up to $250K
- Closes
- Oct 14, 2026
- Who can apply
- State governments, County governments, City or township governments and 12 more
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health- Award range
- Amount not specified
- Closes
- Oct 14, 2026
- Who can apply
- State governments, County governments, City or township governments and 12 more